RESEARCH
Meta-analysis finds PD-1/PD-L1 inhibitors improve survival in pMMR metastatic CRCAcross six randomized trials with 1,165 patients, adding PD-1/PD-L1 inhibitors to chemotherapy with or without anti-VEGF agents prolonged progression-free survival (HR 0.84) and overall survival (HR 0.83) in proficient mismatch repair metastatic colorectal cancer. (Frontiers in Oncology)